SAN DIEGO--(BUSINESS WIRE)--Ambit Biosciences today announced the formation of clinical advisory boards that will help the company advance its drug candidates in development for the treatment of blood cancers and solid tumors. The first advisory board will be focused on hematology and oncology, and the second will focus on solid tumors. The boards will guide Ambit on the development and implementation of the company’s clinical programs for its kinase inhibitors, including AC220 for acute myeloid leukemia (AML) and AC480 for solid tumors.
